$HIMS (+0,29 %) 🚀🚀🚀

The FDA is keeping tirzepatide on the list of shortage drugs. As evidence of the shortage, it also cites "steady and growing" demand from compounders such as $HIMS (+0,29 %) .

This is a good sign that semaglutide will remain on the shortage list.

Updated by the FDA on December 19, 2024.

Full link to the document:

https://storage.courtlistener.com/recap/gov.uscourts.txnd.395430/gov.uscourts.txnd.395430.30.0.pdf